Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Impact of Weizmannella Coagulans BC99 on Protein Digestion and Metabolism: A Randomized, Double-Blind Controlled Trial

NCT06307821 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06307821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06307821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Impact of Weizmannella Coagulans BC99 on Protein Digestion and Metabolism: A Randomized, Double-Blind Controlled Trial
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
February 25, 2024
Completion date
July 30, 2024
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy